← Back to Screener
Lexeo Therapeutics, Inc. Common Stock (LXEO)
Price$4.81
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)-58.24%
Price vs S&P 500 (4W)-15.89%
VGM Score42.55
Market Capitalization$403.60M
All Metrics
Book Value / Share (Quarterly)$3.12
P/TBV (Annual)3.95x
Indicated Dividend (Annual)$0.00
Cash Flow / Share (Quarterly)$-1.33
Price vs S&P 500 (YTD)-59.17%
Net Profit Margin (TTM)-11991.84%
EPS (TTM)$-1.45
10-Day Avg Trading Volume0.80M
EPS Excl Extra (TTM)$-1.45
EPS (Annual)$-3.06
ROI (Annual)-82.89%
Cash / Share (Quarterly)$2.61
ROA (Last FY)-66.69%
EBITD / Share (TTM)$-1.48
ROE (5Y Avg)-56.75%
Operating Margin (TTM)-12408.36%
Cash Flow / Share (Annual)$-1.36
P/B Ratio1.74x
P/B Ratio (Quarterly)1.84x
Net Income / Employee (Annual)$-1,661,000
Net Interest Coverage (TTM)-33.33x
ROA (TTM)-41.72%
EPS Incl Extra (Annual)$-3.06
Current Ratio (Annual)11.21x
Quick Ratio (Quarterly)13.61x
3-Month Avg Trading Volume0.86M
52-Week Price Return79.09%
Revenue / Employee (TTM)$0
Tangible BV / Share (Quarterly)$1.68
P/S Ratio (Annual)620.92x
Asset Turnover (Annual)0.01x
52-Week High$10.99
EPS Excl Extra (Annual)$-3.06
26-Week Price Return-42.31%
Quick Ratio (Annual)10.81x
13-Week Price Return-25.51%
Total Debt / Equity (Annual)0.00x
Current Ratio (Quarterly)14.16x
Enterprise Value$332.56M
Revenue / Employee (Annual)$0
Pretax Margin (Annual)-9120.00%
Cash / Share (Annual)$2.49
3-Month Return Std Dev71.32%
Net Income / Employee (TTM)$-1,483,100
ROE (Last FY)-83.87%
EPS Basic Excl Extra (Annual)$-3.06
Total Debt / Equity (Quarterly)0.00x
EPS Incl Extra (TTM)$-1.45
ROI (TTM)-47.24%
P/S Ratio (TTM)535.16x
Revenue / Share (Annual)$0.00
Tangible BV / Share (Annual)$2.92
Price vs S&P 500 (52W)50.89%
Year-to-Date Return-48.24%
5-Day Price Return0.59%
EPS Normalized (Annual)$-3.06
ROA (5Y Avg)-45.95%
Net Profit Margin (Annual)-9120.00%
Month-to-Date Return-9.75%
Cash Flow / Share (TTM)$-2.56
EBITD / Share (Annual)$-3.29
Operating Margin (Annual)-9309.23%
LT Debt / Equity (Annual)2.29x
ROI (5Y Avg)-55.88%
LT Debt / Equity (Quarterly)3.51x
EPS Basic Excl Extra (TTM)$-1.45
P/TBV (Quarterly)6.87x
P/B Ratio (Annual)2.94x
Pretax Margin (TTM)-11991.84%
Book Value / Share (Annual)$3.38
Price vs S&P 500 (13W)-35.25%
Beta1.38x
Revenue / Share (TTM)$0.00
ROE (TTM)-47.48%
52-Week Low$2.66
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.25est. -0.32
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.41
4.41
4.41
4.41
Industry Peers — Biological Products(178)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
LXEOLexeo Therapeutics, Inc. Common Stock | — | — | C | $4.81 |
| AMGNAmgen Inc | C | C | C | $329.13 |
| GILDGilead Sciences Inc | C | B | C | $131.10 |
| ARGXargenx SE American Depositary Shares | D | A | C | $836.09 |
| RVMDRevolution Medicines, Inc. Common Stock | F | — | A | $163.68 |
| BIIBBiogen Inc. Common Stock | B | D | B | $192.23 |
| BNTXBioNTech SE American Depositary Share | C | C | C | $91.70 |
| MRNAModerna, Inc. Common Stock | C | B | B | $46.06 |
| NBIXNeurocrine Biosciences Inc | C | B | B | $161.00 |
| EXELExelixis Inc | C | B | B | $50.28 |
| KRYSKrystal Biotech, Inc. Common Stock | D | B | B | $298.10 |
About
Lexeo Therapeutics is a clinical-stage biopharmaceutical company focused exclusively on developing gene therapies for hereditary and acquired genetic diseases with high unmet medical needs. The company applies genetic medicine approaches to address conditions with limited existing treatment options.